Use of Black Cohosh and Red Clover for the Relief of Menopausal Symptoms
Overview
This Phase II study, a follow-up to a Phase I trial in normal volunteers, will determine the efficacy of black cohosh and red clover for the relief of menopausal symptoms. It will also assess the safety of chronic dosing (1 year) by evaluating uterine (endometrial biopsies), breast (mammography), and hematology parameters (CBC and chemistry lab values) at baseline and 1 year.
Full Title of Study: “Black Cohosh and Red Clover Efficacy for the Relief of Menopausal Symptoms”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double
Interventions
- Drug: Cimicifuga racemosa
- Drug: Trifolium pratense
- Drug: Black cohosh
- Drug: Red clover
Participating in This Clinical Trial
Inclusion Criteria
- Menopausal women with intact uterus – Must be experiencing hot flashes – No menstrual periods for at least 6 months and no longer than 3 years – Non-smoker – Must have intact uterus (no hysterectomy) Exclusion Criteria:
- Contraindications for hormone replacement therapy – Diabetes mellitus – Pregnancy or breast-feeding – Obese (BMI >35 excluded) – History of endometrial hyperplasia/neoplasia/malignancy – History of breast or reproductive cancer – History of severe recurrent depression, or severe psychiatric disturbance – History of stroke/CVA, severe varicose veins, sickle cell anemia, myocardial infarction (heart attack), or arrhythmia (rhythm disturbance of the heart) – History of abnormal vaginal bleeding of unknown cause – Untreated or uncontrolled high blood pressure/hypertension – Use of any medication or supplement containing estrogen, progestin, SERM, St. John's Wort, bisphosphonates, or phytoestrogens – History of hormone-associated migraines – History of deep vein thrombosis (blood clots), thrombophlebitis, or thromboembolic disorders – Participation in a clinical trial within 30 days – Abnormal endometrial biopsy or mammogram – Abnormal transvaginal ultrasound defined as >7mm thickness – Vegan
Gender Eligibility: Female
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- Collaborator
- Office of Dietary Supplements (ODS)
- Overall Official(s)
- Stacie Geller, MD, Principal Investigator, Department of Obstetrics and Gynecology University of Illinois, Chicago
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.